Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD (NCT05612035)
A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Who can join: Review the eligibility criteria below.
Location: UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110) — San Francisco, California
Age range: 40 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (85 Sites)
Showing the first 25 of 85 sites.
- UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110) — San Francisco, California
- University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0101) — Aurora, Colorado
- Clinovation Intl. Corp. ( Site 0108) — Sebring, Florida
- Alexian Brothers Medical Center-Pulmonary ( Site 0109) — Elk Grove Village, Illinois
- University of Iowa ( Site 0103) — Iowa City, Iowa
- University of Kansas Medical Center-IM-Pulmonary and Critical Care Medicine ( Site 0102) — Kansas City, Kansas
- Lexington VA Medical Center - Cooper Division ( Site 0137) — Lexington, Kentucky
- Corewell Health ( Site 0133) — Grand Rapids, Michigan
- Mayo Clinic in Rochester, Minnesota ( Site 0131) — Rochester, Minnesota
- Creighton University Clinical Research Office ( Site 0123) — Omaha, Nebraska
- University of New Mexico Hospital ( Site 0146) — Albuquerque, New Mexico
- UNC Health - Eastowne Medical Office-Clinical Trials Unit ( Site 0147) — Chapel Hill, North Carolina
- Temple University Hospital ( Site 0104) — Philadelphia, Pennsylvania
- UPMC Montefiore University Hospital-Department of Medicine ( Site 0149) — Pittsburgh, Pennsylvania
- UT Southwestern Medical Center ( Site 0114) — Dallas, Texas
- The University of Texas Health Science Center at Houston ( Site 0105) — Houston, Texas
- Intermountain Medical Center-Division of Pulmonary & Critical Care Medicine ( Site 0140) — Murray, Utah
- University of Virginia Health System-Division of Pulmonary and Critical Care Medicine ( Site 0111) — Charlottesville, Virginia
- Fundación Respirar ( Site 0305) — CABA, Buenos Aires
- Centro Medico Capital ( Site 0301) — La Plata, Buenos Aires
- Instituto de Cardiologia de Tucuman-Area de Investigacion Clinica ( Site 0303) — San Miguel de Tucumán, Tucumán Province
- Hospital Britanico de Buenos Aires ( Site 0307) — CABA,
- Hospital Privado Universitario de Córdoba-Clinical Cardiology Department ( Site 0302) — Córdoba,
- Royal Prince Alfred Hospital-Department of Respiratory Medicine ( Site 0903) — Camperdown, New South Wales
- Westmead Hospital ( Site 0902) — Westmead, New South Wales
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Hypertension
- Trans-pulmonary Biomarkers in Pulmonary Hypertension — Nashville, Tennessee
- Activity Monitoring in Pulmonary Hypertension — Nashville, Tennessee
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF — Tucson, Arizona
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) — Phoenix, Arizona
- A Study of Mosliciguat in PH-ILD — Phoenix, Arizona
Explore by condition: All Pulmonary Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.